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Summary.-Growth of syngeneic transplants of a 3-methylcholanthrene induced rat
sarcoma was suppressed when tumour cells were injected in admixture with BCG.
Rejection of these mixed inocula resulted in the suppression of growth of a simul-
taneous challenge with cells of the same tumour at a contralateral subcutaneous site
and conditions for immunotherapy were evaluated with respect to the maximum
tumour cell challenge rejected and the optimum time of treatment. These studies"
established that viable tumour cells were more effective than radiation attenuated
cells for the immunizing stimulus. Also, the maximum tumour challenge totally
rejected in this way was of the order of 106 cells, and with this rapidly growing
tumour, treatment had to be initiated within 4 days of tumour injection. These
observations are relevant to current proposals for adjuvant immunotherapy of
human malignant disease where conditions of minimal residual disease are not
being fulfilled.
IMMUNOTHERAPY is now being viewed
as a feasible component of the treatment
of human malignant disease. This is based
firstly upon the evidence that many
cancer patients elicit an immune response
against neoantigens associated with their
own tumours as demonstrated by the in
vitro cytotoxicity of peripheral lympho-
cytes for cultured tumour cells (Hellstr6m
et al., 1971). Secondly, immunostimula-
tion by nonspecific adjuvants such as
Bacillus Calmette-Guerin (BCG) and
Corynebacterium parvum has been used to
induce rejection or to retard growth of
syngeneic transplants of a number of
experimental animal tumours (Mathe,
Pouillart and Lapeyraque, 1969; Parr
1972; Bansal and Sj6gren, 1973; Currie
and Bagshawe, 1970; Woodruff and Boak,
1966). Recent experimental investiga-
tions, however, have established that
direct contact between viable BCG organ-
isms and tumour cells produces a more
marked suppression of tumour growth
than that elicited by general immuno-
20
stimulation. Thus syngeneic transplants
of several tumours, including diethyl-
nitrosamine induced guinea-pig hepato-
mata (Zbar, Bernstein and Rapp, 1971)
and 3-methylcholanthrene induced sarco-
mata in rats (Baldwin and Pimm, 1971)
and mice (Bartlett, Zbar and Rapp, 1972),
are suppressed when tumour cells are
injected locally in admixture with BCG.
Infection of established tumours may also
lead to their rejection (Zbar et al., 1972;
Baldwin and Pimm, 1971). In addition to
the retardation of localized tumour de-
velopment, BCG infection of subcutane-
ous grafts of a transplanted guinea-pig
hepatoma prevented the development of
lymph node metastases (Zbar et al., 1972)
and similar treatment of a rat epithelioma
restricted or retarded the formation of
pulmonary metastases (Baldwin and
Pimm, 1973a). The rationale of directly
contacting BCG with tumour cells has also
been used to suppress the development of
pulmonary metastasesproducedartificia]ly
in rats by intravenous injection of sarco-R. W. BALDWIN AND M. V. PIMM
mata cells (Baldwin and Pimm, 1973b) or
developing spontaneously from a trans-
planted epithelioma (Baldwin and Pimm,
1973a) by subsequent intravenous injec-
tion of BCG.
The objective of the present studies,
using a 3-methylcholanthrene (Mc) in-
duced sarcoma with defined immuno-
genicity, was to evaluate the maximum
tumour burden in terms of transplanted
tumour cells which can be reproducibly
treated by deliberate tumour infection
with BCG. Rejection of sarcoma-BCG
mixed inocula is known to induce suppres-
sion of growth of the same tumour im-
planted at another site (Baldwin and
Pimm, 1971) and the conditions for active
immunotherapy have been defined in
terms of the maximum tumour cell
challenge which couldbe controlled andthe
optimum time of treatment. In this way
it has been possible to define conditions
whereby subcutaneous growth of this
tumour can be controlled, these observa-
tions being relevant in defining conditions
where adjuvant immunotherapy ofhuman
malignant disease might be appropriate.
MATERIALS AND AIETHODS
Tumour. Sarcoma Mc7 was induced in an
adult female rat of an inbred Wistar strain by
subcutaneous injection of 3-methylcholan-
threne (5 mg) in trioctanoin. The tumour
was maintained by subcutaneous transplanta-
tion in syngeneic rats of the same sex as the
primary donor. and in the preseiit studies had
not been transferred for more than 15 trans-
plant generations. This sarcoma is highly
immunogenic, animals immunized by excision
of subcutaneous growths subsequently reject-
ing challenge with 5 x 106 tumour cells or
whole tumour grafts.
Single cell suspensions were prepared by
digestion ofminced tissue in 0-25% trypsin in
Hank's balanced salt solution and resuspen-
sion in medium 199, their viability as deter-
nlined by trypan blue exclusion being at least
900g.
Bacillus Calmette-Gue'rin (BCG). Freeze-
dried vaccine (percutaneous) was supplied by
Glaxo Laboratories Ltd, Greenford, Middle-
sex, England. On reconstitution in w%ater the
vaccine contained 3 x 108 viable organisms
in 10 mg moist weight/ml. In some tests the
effect of the vaccine freeze-drying medium
(dextran 8-3% w/v, glucose 7.50% w/v, Triton
WR 1339 1/4000 v/v) was compared with the
response to BCG.
Methods of treatment.-To determine the
influence of localized BCG on the growth- of
sarcoma Mc7, defined numbers of viable
sarcoma cells were mixed with known
amounts of BCG (expressed as mg moist
weight of organisms) and immediately in-
jected subcutaneously. Control rats received
tumour cells in medium 199 alone, or mixed
with BCG freeze-drying medium. Tumours
were measured Mweekly w%Nith calipers and
average diameters calculated from measure-
ments in 2 planes. Active immunotherapy
of subcutaneous challenge inocula of sarcoma
Mc7 was given by injection at a contralateral
subcutaneous site of viable, or 60Co y-irradi-
ated (15,000 rad), tumour cells in admixture
with viable BCG.
RESULTS
Influence of localized BCG on subcutaneous
growth of sarcoma Mc7
Previous studies with sarcoma Mc7
(Baldwin and Pimm, 1971) have establish-
ed that admixture with at least 100 ,tg
moist weight of BCG organisms is neces-
sary to consistently inhibit growth of an
inoculum of 5 x 105 tumour cells. Based
upon these results, the maximum tumour
cell inoculum suppressed when injected
subcutaneously together with a standard
dose (200 ,ug moist weight) of BCG was
determined (Table I). Almost complete
suppression of growth from 5 x 105 to
2 x 106 sarcoma Mc7 cells was observed
but beyond this cell number BCG infection
of inocula did not consistently inhibit
growth. Thus with an inoculum of
5 x 106 cells complete suppression of
growth was observed in one test, but in a
second only retarded tumour development
occurred in 3/4 animals receiving the
mixed cell inoculum (Fig. 1). Further-
more, only partial inhibition of tumour
development was observed from an inocu-
lum of 1 x 107 cells mixed with 200 ,ug of
BCUG.
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TABLE I.-Growth ofSubcutaneous Inocula ofSarcoma Mc7 Cells in Admixture with BCG
Mixed cell inoculum
No. tumour BCG ,ug
cells moist weight
5 x 105 200
1 x106 200
2 x 106 200
5x 106 200
1 X 106
2 x 106
5x 106
1 X 107
200
200
200
200
Tumour takes in
Treated
rats Controls
0/4 4/4
0/4 4/4
1/5 4/5
0/4 4/4
0/5
1/5
3/4
2/4
4/4
5/5
4/4
2/2
3 7-5x107 1200 5/5 5/5*
* Control rats received sarcoma Mc7 cells mixed with BCG freeze-drying medium.
TABLE- II.-Active Immunotherapy ofSarcoma Mc7 with Viable Tumour Cells
Preventedfrom Growth by Admixture with BCG
Tumour
challenge
Experiment (cells)
1 2x105
5 x 105
1 X 106
2
3
4
1 X 106
2-5x 106
5 x 106
5x 105
1 X 106
Contralateral inoculum
Day
0
0
0
0
0
0
0
2
4
7
0
2
4
7
Tumour cell
dose
1 X 106
1 X 106
1 X 106
2 x 106
2x 106
2 x 106
2 x 106
2 x 106
2x 106
2 x 106
2 x 106
2 x 106
2x 106
2 x 106
BCG ,g
moist weight
200
200
200
500
500
500
500
500
500
500
500
500
500
500
Tumour growth in
A_
Treated
rats Controls
0/4 4/4
0/4 3/4
1/4 4/4
0/4
4/4
4/4
0/4
1/4
2/4
4/4
0/4
2/4
3/4
3/4
5/5
5/5
4/4
4/4
4/5
In a further experiment, the influence
of an increased dose ofBCG (1.2 mg moist
weight) on the growth of 7 5 X 107
sarcoma Mc7 cells was examined, but
tumour takes (5/5) and growth rates were
comparable with those in animalsreceiving
tumour cells in admixture with the BCG
freeze-drying medium.
Active immunotherapy of sarcoma Mc7
It has previously been demonstrated
(Baldwin and Pimm, 1971) that rejection
ofaBCG-sarcomaMc7 mixed cellinoculum
resulted in suppression of a simultaneous
challenge with 5 x 105 cells of the same
Experiment
1
2
TIME (DAYS)
FIG. 1.-Growth ofsarcoma Mc7 (5 x 106 cells)
injected subcutaneously alone (E1-C]) or in
admixture with BCG (200 ,ug moist weight
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FIG. 2. Growth of challenge inocula of sarcoma AMc7 (5 x 105 cells) in animals receiving immuno-
therapy. Treatment was given by a contralateral subcutaneous injection of tumour cells (2 x 106)
in admixture with BCG (500 jug moist weight).
TABLE III. Active I mnaunotherapy ofSarcoma Mc7 with Viable or Irradiated
Tumour Cells in Admixture with BCG
Tumour
challenge
(cells)
1 x 106
1 X 106
Contralateral inoculum
, ~~~~~~~~~~~'
BCG [kg
Tumour cells moist weight
2 x106 viable 500
2 x 106 irradiated* 500
1 x 106 2 x 106 viable
1 x 106 5 x 106 irradiated*
* Cells exposed to 15,000 rad y-irradiation.
500
500
Tumour takes in
, ~ ~ ~~AA
Treated
rats Controls
0/4 7/8
2/4
0/4
2/4
8/10
GROUP
CONTROL
10 20
TIME (DAYS)
30
Aft
m
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tumour at another subcutaneous site.
Further tests were therefore carried out to
determine the maximum cell inoculum
which could be controlled by this form of
active immunotherapy. In the first ex-
periment (Table II) groups of rats were
challenged subcutaneously with 2 x 105
to 1 x 106 sarcoma Mc7 cells and simul-
taneously received a contralateral sub-
cutaneous injection of 1 x 106 cells in
admixture with 200 ,ag of BCG. No
growth occurred at the site of the mixed
inoculum and this treatment prevented
growth of challenge inocula of 2 x 105
and 5 x 105 Mc7 cells in all rats and 3/4
animals challenged with 1 x 106 cells. In
the second experiment an attempt was
made to control challenge inocula of up to
5 x 106 cells, by treating animals simul-
taneously with 2 x 106 cells together with
500 ,ag of BCG. In this case growth from
a challenge of 1 x 106 cells was completely
suppressed, but tumours developed in all
rats receiving inocula of 2-5 x 106 and
5 x 106 cells. However, even in those
animals which developed tumours at the
site of challenge with cells alone, no
growth was observed at the site of injec-
tion of tumour cells together with BCG.
Having established that active im-
munotherapy of sarcoma Mc7 could con-
trol tumour growth from challenge inocula
of 2 X 105to 1 X 106 cells, further experi-
ments were carried out to determine the
effect of delaying treatment for several
days after challenge with Mc7 cells
(Table II). In the experiment illustrated
in Fig. 2, simultaneous treatment of a
challenge (5 x 105 cells) with a contra-
lateral inoculum of 2 x 106 viable Mc7
cells together with 500,jag of BCG pre-
vented progressive growth in all rats
(Group II). Nevertheless, all of these
treated animals developed palpable tu-
mour nodules (mean diameters 0-2-0.6 cm)
at the challenge site within 9 days, but
these subsequently regressed. Even when
immunotherapy was delayed until 2 days
after challenge (Group III), progressive
tumourgrowth occurred in only 1/4 treated
rats, and this was retarded compared with
growth in untreated controls (Group I).
Furthermore, although one other treated
rat developed a tumour at the challenge
site which developed to 1 cm mean
diameter, this subsequently underwent
total regression. In a third group of rats
(Group IV), treatment was given 4 days
after the initial challenge with 5 X 105
cells, and in this case progressive growth
occurred in only 2/4 animals. The re-
maining 2 rats exhibited transient growth
at the challenge site, subsequently becom-
ing free of palpable tumour. With a
further group ofanimals, (Group V), treat-
ment was delayed for 7 days, by which
time palpable tumournoduleshaddevelop-
ed at the challenge sites. In this case
treatment was unsuccessful, tumour
growth occurring in all 4 rats, at rates
comparable with the control animals
(Group I).
Throughout this experiment, no tu-
mour growth occurred at the site of the
treatment inoculum containing viable
sarcoma cells and BCG, even in those rats
in which the challenge inocula were not
controlled.
In view of the successful immuno-
therapy of up to 1 x 106 sarcoma Mc7
cells by a subcutaneous contralateral
injection of viable tumour cells in ad-
mixture with BCG, further tests were
carried out to compare the effectiveness of
this form oftreatment with that produced
using heavily irradiated (15,000 rad) cells.
These experiments (Table III) showed that
while a standard inoculum of 2 x 106
viable Mc7 cells together with 500 ,ug of
BCG suppressed a simultaneous challenge
with 1 X 106 cells in all (8/8) treated rats,
inhibition ofgrowth was obtained in only a
proportion (4/8) ofanimalswhenirradiated
cells were used together with BCG for
immunotherapy, including a test in which
the number ofirradiated cells in the treat-
ment inoculum was increased to 5 x 106.
DISCUSSION
These and previous studies (Baldwin
and Pimm, 1971) have established that
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growth of syngeneic transplants of Mc-
induced rat sarcoma cells can be suppres-
sed by injection in admixture with BCG,
and this produces rejection of a simul-
taneous challenge with the same tumour at
a contralateral site. XVith one of these
sarcomata (Mc7), a dose of at least 100 jig
moist weight ofBCG percutaneous vaccine
(Glaxo) is necessary to consistently inhibit
growth ofa tumour cell inoculum (5 x 105
cells) which grows progressively in control
rats. The present studies have establish-
ed that the maximum tumour cell inocu-
lum consistently rejected when injected
together with BCG is 2 x 106 cells, this
being approximately ten-fold greater than
the threshold number for progressive
growth of this sarcoma. This therefore
defines the maximum dose of viable Mc7
cells which can be safely administered in
admixture with BCG (100 ltg moist weight
or more) for active immunotherapy ofthis
immunogenic tumour.
Quantitation oftheimmunotherapeutic
response ofsarcoma Mc7 established that a
challenge of up to 1 x 106 cells could be
eliminated completely by a simultaneous
contralateral injection of sarcoma cells
(2 x 106) in admixture with BCG (200-
500 ,tg moist weight). These treatment
inocula of tumour cells and BCG con-
sistently failed to develop, even when the
contralateral challenge inocula were too
large to be controlled. Immunotherapy
was also effective when initiated up to
4 days after tumour challenge, producing
complete or partial regression of tumour
growth but after 7 days, when the animals
had developed palpable tumours, it was
completely ineffective. Viable sarcoma
cells mixed with BCG were more efficient
for immunotherapy than comparable num-
bers of y-irradiated cells together with
viable BCG organisms.
In comparable studies with an intra-
dermally transplanted guinea-pig hepa-
toma, Bartlett and Zbar (1972) were able
to consistently suppress challenge inocula
of only ] x 105 tumour cells by active
immunotherapy with viable hepatoma
cells in admixture with BCG. Further-
more, treatment inocula of viable cells
together with BCG, which otherwise failed
to develop, occasionally grew progres-
sively in guinea-pigs receiving large chal-
lenge inocula at contralateral intradermal
sites. Also, in contrast to the present
studies, heavily irradiated hepatoma cells
together with BCG were as effective as
unirradiated cells for immunotherapy.
Immunoprotection tests with sarcoma
Mc7 used in the present studies indicate
that the maximum tumour cell challenge
rejected in rats immunized by repeated
implantation of irradiated tumour or
excision of growing tumour grafts is at
least 5 x 106 cells. It is evident, there-
fore, that the immunotherapeutic tech-
niques so far developed, which can control
challenge inocula of only I x 106 cells,
cannot filly activate the immunological
capacity ofthe host. This may reflect the
limited recruitment of sensitized lympho-
cytes during the short duration of tests
with fast growing transplanted tumours
such as sarcoma Mc7, and possibly the
influence of antagonistic humoral factors,
such as circulating tumour antigen or
antigen-antibody complexes, during tu-
mour growth (Baldwin, Price and Robins,
1973). In this context it should be noted
(Fig. 2) that even in rats successfully
treated by contralateral immunization
with sarcoma cell-BCG inocula, tumours
developed for a limited period at the chal-
lenge site before undergoing regression.
These observations suggest that effective
active immunotherapy is dependent upon
subtle responses, possibly controlling the
relative levels of sensitized lymphocytes
and circulating blocking factors. Thishas
been postulated by Bansal and Sjogren
(1973) who correlated the influence of
BCG therapy on growth inhibition of
transplanted polyoma rat tumours with
increased levels of cytotoxic lymphocytes.
This effect was observed when BCG was
given intracutaneously before or at the
time of tumour implantation. Enhance-
ment of tumour growth rather than sup-
pression was observedwhenBCGwasgiven
at the time when palpable tumour nodules
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were present, and this correlated with an
increased serum blocking activity and no
great change in the level of cell mediated
immunity. Since in vitro correlations of
the immune response elicited by sarcoma
Mc7-BCG mixed inocula have not yet
been analysed, discussion of the role of
blocking serum factors is not appropriate.
The present studies do indicate, however,
that active immunotherapy with BCG
vaccine in admixture with tumour cells is
feasible. These studies emphasize again
that BCG in contact with tumour cells is an
essential requirement. Even with highly
immunogenic tumours, however, the con-
ditions of treatment must be carefully
controlled if a positive response is to be
achieved.
This work was supported by the Cancer
Research Campaign. We thank Glaxo
Research Ltd who kindly supplied the
BCG vaccine.
REFERENCES
BALDWIN, R. W. & PIMM, M. V. (1971) Influence of
BCG Infection on Growth of 3-methylchol-
anthrene-induced Rat Sarcomas. Eur. J. clin.
biol. Res., 16, 875.
BALDWIN, R. W. & PIMM, M. V. (1973a) BCG Im-
munotherapy of Local Subcutaneous Growths and
Post-surgical Pulmonary Metastases of a Trans-
planted Rat Epithelioma of Spontaneous Origin.
Int. J. Cancer. In the press.
BALDWIN, R. W. & PIMM, M. V. (1973b) BCG Im-
munotherapy of Pulmonary Growths from Intra-
venously Transferred Rat Tumour Cells. Br. J.
Cancer, 27, 48.
BALDWIN, R. W., PRICE, M. R. & ROBINS, R. A.
(1973) Significance of Serum Factors Modifying
Cellular Immune Responses to Growing Tumours.
Br. J. Cancer. In the press.
BANSAL, S. C. & SJoGREN, H. 0. (1973) Effects of
BCG on Various Facets of the Immune Response
against Polyoma Tumors in Rats. Int. J. Cancer,
11, 162.
BARTLETT, G. L. & ZBAR, B. (1972) Tumor-specific
Vaccine containing Mycobacterium bovis and
Tumor Cells: Safety and Efficacy. J. natn.
Cancer Inst., 48, 1709.
BARTLETT, G. L., ZBAR, B. & RAPP, H. J. (1972)
Suppression of Murine Tumor Growth by Im-
mune Reaction to the Bacillus Calmette-Guerin
Strain of Mycobacterium bovis. J. natn. Cancer
Inst., 48, 245.
CURRIE, G. A. & BAGSHAWE, K. D. (1970) Active
Immunotherapy with Corynebacterium parvum
and Chemotherapy in Murine Fibrosarcomas.
Br. med. J., i, 541.
HELLSTR6M, I., HELLSTROM, K. E., SJ6GREN, H. 0.
& WARNER, G. A. (1971) Demonstration of Cell-
mediated Immunity to Human Neoplasms of
Various Histological Types. Int. J. Cancer, 7, 1.
MATHII, G., POUILLART, P. & LAPEYRAQUE, R. (1969)
Active Immunotherapy of L1210 Leukaemia
Applied after the Graft of Tumour Cells. Br. J.
Cancer, 23, 814.
PARR, I. (1972) Response of Syngeneic Murine
Lymphomata to Immunotherapy in Relation to
the Antigenicity of the Tumour. Br. J. Cancer,
26, 174.
WOODRUFF, M. F. A. & BOAK, J. L. (1966) Inhibitory
Effects ofInjection of C. parvum on the Growth of
Tumour Transplants in Isogeneic Hosts. Br. J.
Cancer, 20, 345.
ZBAR, B., BERNSTEIN, I. D. & RAPP, H. J. (1971)
Suppression of Tumor Growth at the Site of
Infection with Living Bacillus Calmette-Guerin.
J. natn. Cancer Inst., 46, 831.
ZBAR, B., BERNSTEIN, I. D., BARTLETT, G. L.,
HANNA, M. G. & RAPP, H. J. (1972) Immuno-
therapy of Cancer: Regression of Intradermal
Tumors and Prevention of Growth of Lymph
Node Metastases after Intralesional Injection of
Living Mycobacterium bovis. J. natn. CancerIn8t.,
49, 119.